HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

Galectin Therapeutics -0.76%

Galectin Therapeutics

GALT

1.31

-0.76%

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ: GALT) with a Buy and maintains $11 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via